DiaMedica Therapeutics financials
$8.20−1.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$10.5M | -$10.5M | -$9.2M | -$9.0M | -$8.0M | -$8.1M | -$8.4M | -$6.9M | -$5.6M | -$5.7M | -$5.8M | -$5.2M |
| Net income | -$10.2M | -$10.0M | -$8.7M | -$8.6M | -$7.7M | -$7.7M | -$7.9M | -$6.3M | -$5.1M | -$5.2M | -$5.2M | -$4.5M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.19 | $-0.19 | $-0.17 | $-0.17 | $-0.18 | $-0.18 | $-0.18 | $-0.15 | $-0.13 | $-0.14 | $-0.13 | $-0.12 |
| EBITDA | -$10.5M | -$10.5M | -$9.2M | -$9.0M | -$8.0M | -$8.1M | -$8.4M | -$6.9M | -$5.6M | -$5.7M | -$5.8M | -$5.1M |
| Operating cash flow | -$8.1M | -$9.1M | -$7.8M | -$6.5M | -$7.6M | -$7.1M | -$6.4M | -$4.5M | -$4.5M | -$6.7M | -$3.8M | -$4.8M |
| Free cash flow | -$8.1M | -$9.1M | -$7.8M | -$6.6M | -$7.6M | -$7.2M | -$6.4M | -$4.5M | -$4.5M | -$6.7M | -$3.8M | -$4.8M |
| Diluted shares | 53.9M | 53.8M | 52.5M | 49.6M | 43.0M | 42.8M | 42.8M | 42.8M | 38.1M | 38.0M | 38.6M | 37.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.1M | $4.9M | $15.6M | $3.3M | $4.1M | $2.6M |
| Short-term investments | $38.4M | $46.5M | $44.2M | $52.0M | $25.9M | $33.7M |
| Total debt | $9.0K | $12.0K | $15.0K | $17.0K | $20.0K | $22.0K |
| Total assets | $45.0M | $53.1M | $61.4M | $57.0M | $31.5M | $38.8M |
| Total liabilities | $6.7M | $5.8M | $5.3M | $5.4M | $4.3M | $4.9M |
| Shareholders' equity | $38.3M | $47.2M | $56.1M | $51.6M | $27.2M | $34.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology